뇌졸중 환자 수 분석과 예측(2026-2035년)

Stroke is a neurological emergency caused by an interruption of blood flow to the brain or bleeding within the brain, resulting in neurological impairment of varying severity. It remains one of the leading causes of death and disability worldwide, placing a substantial burden on healthcare systems, caregivers, and society. Patient population analysis provides valuable insights into disease prevalence, incidence, demographic distribution, diagnosed and treated populations, disease severity, recurrence rates, and future epidemiological trends to support healthcare planning, pharmaceutical development, and commercial decision-making.

Market Drivers

Rising Global Burden of Stroke

Population aging, increasing life expectancy, urbanization, sedentary lifestyles, and the growing prevalence of cardiovascular risk factors continue to increase the global burden of stroke. Although age-standardized rates have declined in many countries, the absolute number of stroke patients continues to rise because of demographic changes.

Aging Population

Stroke incidence increases significantly with age. The continued expansion of the elderly population worldwide is expected to drive growth in both incident and prevalent stroke populations over the coming decades.

Improved Acute Stroke Survival

Advances in emergency stroke care, thrombolytic therapy, mechanical thrombectomy, and rehabilitation have improved survival rates, resulting in a growing population of individuals living with long-term neurological disability following stroke.

Increasing Awareness and Diagnosis

Greater public awareness of stroke symptoms, improved diagnostic imaging, and expanded access to specialized stroke centers are contributing to earlier diagnosis and improved epidemiological reporting.

Market Restraints

Underdiagnosis in Low-Resource Settings

Limited healthcare infrastructure, inadequate access to diagnostic imaging, and shortages of stroke specialists continue to result in underdiagnosis and underreporting in several low- and middle-income countries.

Variability in Epidemiological Reporting

Differences in national healthcare systems, disease registries, diagnostic criteria, and reporting methodologies create variability in epidemiological estimates across geographic regions.

Healthcare Access Inequalities

Delayed access to emergency stroke care and rehabilitation services continues to affect patient outcomes and epidemiological surveillance in many developing healthcare systems.

Patient Population Insights

The global stroke patient population can be segmented by stroke type, disease severity, age group, gender, diagnosis status, treatment status, and geography.

By stroke type, the patient population includes ischemic stroke, hemorrhagic stroke, and transient ischemic attack (TIA). Ischemic stroke represents the largest proportion of cases globally, accounting for the majority of diagnosed patients.

By disease severity, patients are categorized into mild, moderate, and severe stroke, with severe stroke patients generally requiring prolonged hospitalization, rehabilitation, and long-term supportive care.

By age group, the analysis includes pediatric, adult, and geriatric populations. Older adults account for the largest share of stroke patients, although stroke incidence among younger adults has increased because of changing lifestyle and metabolic risk factors.

By gender, stroke affects both men and women. Men generally experience slightly higher incidence rates, while women often have a greater lifetime risk because of longer life expectancy.

By diagnosis status, the analysis evaluates diagnosed and undiagnosed patient populations, highlighting opportunities for improved screening and healthcare access.

By treatment status, patients are classified into treated and untreated populations, reflecting disparities in emergency care, rehabilitation access, and long-term secondary prevention.

Epidemiology Trends

The global stroke patient population continues to increase because of demographic and lifestyle changes.

Key trends include:

• Rising absolute numbers of stroke survivors worldwide.
• Increasing prevalence of ischemic stroke.
• Growing burden among aging populations.
• Higher incidence associated with hypertension, diabetes, obesity, and atrial fibrillation.
• Improved survival resulting in larger long-term patient populations.
• Expansion of stroke registries and epidemiological surveillance.
• Increasing demand for long-term rehabilitation and secondary prevention services.

Regional Insights

North America continues to maintain one of the largest diagnosed stroke populations because of comprehensive healthcare infrastructure, advanced diagnostic capabilities, widespread public awareness, and established stroke care networks.

Europe reports a substantial patient burden supported by aging populations, comprehensive stroke registries, and strong rehabilitation services.

Asia-Pacific is expected to experience the fastest growth in stroke patient numbers owing to rapid population aging, increasing prevalence of hypertension and diabetes, improving healthcare access, and enhanced stroke diagnosis across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa continue to experience increasing stroke burden as non-communicable diseases become more prevalent and healthcare systems expand stroke diagnosis and treatment services.

Competitive Landscape

Stroke patient population analysis supports pharmaceutical companies, biotechnology firms, medical device manufacturers, healthcare providers, academic researchers, and policymakers in understanding disease burden and future commercial opportunities.

Organizations increasingly utilize epidemiological data for clinical trial planning, patient recruitment, market forecasting, healthcare resource allocation, reimbursement planning, and commercialization strategy. Integration of real-world evidence, national stroke registries, and electronic health records continues to improve the accuracy of patient population assessments.

Future Outlook

The global stroke patient population is expected to continue expanding through 2035 due to aging populations, increasing prevalence of cardiovascular risk factors, improved survival following acute stroke, and expanding healthcare access. Advances in artificial intelligence, digital health technologies, tele-stroke services, wearable monitoring, and real-world evidence generation are expected to improve patient identification, epidemiological surveillance, and long-term disease management.

Continued investment in stroke prevention, rehabilitation, and population health research will further strengthen understanding of disease burden and support healthcare planning worldwide.

Conclusion

The global Stroke Patient Population Analysis highlights the substantial and growing burden of stroke worldwide. Rising prevalence of cardiovascular risk factors, demographic aging, improved survival, and enhanced disease awareness are expected to drive continued growth in the diagnosed stroke population. Although disparities in healthcare access and epidemiological reporting remain significant challenges, advances in stroke prevention, diagnosis, acute treatment, rehabilitation, and digital health technologies are expected to improve patient outcomes and support more effective healthcare planning.

Key Benefits of this Report

• Comprehensive analysis of the global stroke patient population and epidemiological trends.
• Detailed evaluation of prevalence, incidence, diagnosed, treated, and untreated patient populations.
• Assessment of demographic distribution by age, gender, stroke type, disease severity, and geography.
• Insights into disease burden, unmet clinical needs, and future patient population growth.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Epidemiology forecasting, patient population estimation, clinical trial planning, market opportunity assessment, healthcare resource planning, investment analysis, commercialization strategy, reimbursement planning, and strategic decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global stroke patient population by stroke type, disease severity, age group, gender, diagnosis status, treatment status, and geography
• Evaluation of prevalence, incidence, diagnosed and undiagnosed populations, treated and untreated populations, and epidemiological trends
• Assessment of demographic characteristics, disease burden, healthcare utilization, long-term disability, and unmet clinical needs
• Analysis of regional epidemiology, patient growth trends, stroke risk factors, healthcare infrastructure, and future opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Study Overview
• 1.2 Stroke Disease Burden Overview
• 1.3 Key Epidemiology Insights
• 1.4 Key Demographic Trends
• 1.5 Regional Patient Population Highlights
• 1.6 Country-Level Epidemiology Highlights
• 1.7 Key Risk Factor Assessment
• 1.8 Future Patient Population Outlook
• 1.9 Analyst Conclusions

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Stroke
  • 2.1.1 Definition and Clinical Overview
  • 2.1.2 Disease Classification
  • 2.1.3 Disease Pathophysiology
  • 2.1.4 Disease Progression and Outcomes
• 2.2 Stroke Classification
  • 2.2.1 Ischemic Stroke
  • 2.2.2 Hemorrhagic Stroke
    • 2.2.2.1 Intracerebral Hemorrhage
    • 2.2.2.2 Subarachnoid Hemorrhage
  • 2.2.3 Transient Ischemic Attack (TIA)
• 2.3 Etiology and Risk Factors
  • 2.3.1 Hypertension
  • 2.3.2 Atrial Fibrillation
  • 2.3.3 Diabetes Mellitus
  • 2.3.4 Dyslipidemia
  • 2.3.5 Obesity
  • 2.3.6 Smoking
  • 2.3.7 Alcohol Consumption
  • 2.3.8 Sedentary Lifestyle
  • 2.3.9 Aging Population
  • 2.3.10 Genetic Predisposition
• 2.4 Epidemiology Methodology and Assumptions
  • 2.4.1 Data Sources
  • 2.4.2 Patient Population Modeling Approach
  • 2.4.3 Forecasting Assumptions
• 2.5 Global Stroke Epidemiology
  • 2.5.1 Total Prevalent Cases
  • 2.5.2 Total Incident Cases
  • 2.5.3 Diagnosed Cases
  • 2.5.4 Treated Cases
  • 2.5.5 Mortality Analysis
  • 2.5.6 Disability Burden Assessment
• 2.6 Epidemiology by Stroke Type
  • 2.6.1 Ischemic Stroke Population
  • 2.6.2 Hemorrhagic Stroke Population
  • 2.6.3 TIA Population
• 2.7 Epidemiology by Age Group
  • 2.7.1 Pediatric Population
  • 2.7.2 Adult Population
  • 2.7.3 Elderly Population
• 2.8 Epidemiology by Gender
  • 2.8.1 Male Population
  • 2.8.2 Female Population
• 2.9 Epidemiology by Disease Severity
  • 2.9.1 Mild Cases
  • 2.9.2 Moderate Cases
  • 2.9.3 Severe Cases
• 2.10 Epidemiology of Stroke Recurrence
  • 2.10.1 First-Ever Stroke Cases
  • 2.10.2 Recurrent Stroke Cases
• 2.11 Epidemiology Forecast Analysis

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
  • 3.2.1 Rising Aging Population
  • 3.2.2 Increasing Cardiovascular Disease Burden
  • 3.2.3 Growing Awareness and Diagnosis Rates
  • 3.2.4 Expansion of Stroke Registries and Surveillance Programs
  • 3.2.5 Improvements in Acute Stroke Care
• 3.3 Market Restraints
  • 3.3.1 Underdiagnosis in Developing Regions
  • 3.3.2 Limited Access to Specialized Stroke Centers
  • 3.3.3 Data Gaps in Emerging Markets
• 3.4 Market Opportunities
  • 3.4.1 Digital Health and Stroke Monitoring
  • 3.4.2 AI-Based Risk Prediction
  • 3.4.3 Precision Medicine Approaches
• 3.5 Market Challenges
  • 3.5.1 Epidemiological Variability
  • 3.5.2 Healthcare Access Disparities
  • 3.5.3 Long-Term Disability Burden

4. Commercial & Market Access

• 4.1 Patient Journey Assessment
• 4.2 Diagnosis and Referral Pathways
• 4.3 Treatment Access Landscape
• 4.4 Reimbursement Overview
• 4.5 Public Health Initiatives
• 4.6 Stroke Screening and Prevention Programs
• 4.7 Market Access Challenges
• 4.8 Health Economics and Burden Assessment

5. Innovation & Pipeline Landscape

• 5.1 Innovation Overview
• 5.2 Emerging Therapeutic Approaches
• 5.3 Neuroprotective Therapies
• 5.4 Regenerative Medicine Approaches
• 5.5 Cell Therapy Developments
• 5.6 Gene-Based Research Programs
• 5.7 Digital Therapeutics and Rehabilitation Technologies
• 5.8 Pipeline Analysis by Development Stage
  • 5.8.1 Discovery Stage
  • 5.8.2 Preclinical Stage
  • 5.8.3 Phase I
  • 5.8.4 Phase II
  • 5.8.5 Phase III
• 5.9 Pipeline Analysis by Modality
  • 5.9.1 Small Molecules
  • 5.9.2 Biologics
  • 5.9.3 Cell Therapies
  • 5.9.4 Gene Therapies
  • 5.9.5 Digital Therapeutics
• 5.10 Pipeline Analysis by Mechanism of Action
• 5.11 Clinical Trial Landscape
• 5.12 Emerging Research Collaborations

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Acute Stroke Management
  • 6.2.1 Intravenous Thrombolysis
  • 6.2.2 Mechanical Thrombectomy
  • 6.2.3 Antiplatelet Therapy
  • 6.2.4 Anticoagulant Therapy
• 6.3 Secondary Stroke Prevention
  • 6.3.1 Antiplatelet Agents
  • 6.3.2 Anticoagulants
  • 6.3.3 Lipid-Lowering Therapies
  • 6.3.4 Antihypertensive Therapies
• 6.4 Rehabilitation Landscape
• 6.5 Treatment Guidelines Review
• 6.6 Unmet Medical Needs
• 6.7 Emerging Treatment Trends

7. Global Stroke Patient Population Analysis Size & Forecast

• 7.1 Global Stroke Patient Population Overview
• 7.2 Historical Patient Population Analysis
• 7.3 Forecast Patient Population Analysis
• 7.4 Incident Patient Population Forecast
• 7.5 Prevalent Patient Population Forecast
• 7.6 Diagnosed Patient Population Forecast
• 7.7 Treated Patient Population Forecast
• 7.8 Epidemiology Forecast by Stroke Type
• 7.9 Epidemiology Forecast by Age Group
• 7.10 Epidemiology Forecast by Gender

8. Global Stroke Patient Population Analysis Segmentation

• 8.1 By Stroke Type
  • 8.1.1 Ischemic Stroke
    • 8.1.1.1. Thrombotic
    • 8.1.1.2. Embolic
  • 8.1.2 Hemorrhagic Stroke
  • 8.1.3 Transient Ischemic Attack
  • 8.1.4 Others
• 8.2 By Drug Type
  • 8.2.1 Thrombolytics
  • 8.2.2 Antiplatelets
  • 8.2.3 Anticoagulants
  • 8.2.4 Antihypertensives
  • 8.2.5 Others
• 8.3 By Treatment Type
  • 8.3.1 IV Medication
  • 8.3.2 Endovascular Therapy
  • 8.3.3 Surgical Procedures
    • 8.3.3.1 Mechanical Thrombectomy
    • 8.3.3.2 Carotid Endarterectomy (CEA)
    • 8.3.3.3 Others
• 8.4 By Severity Type
  • 8.4.1 Mild
  • 8.4.2 Moderate
  • 8.4.3 Severe
• 8.5 By Age-Group
  • 8.5.1 Below 20 Years
  • 8.5.2 20 to 50 Years
  • 8.5.3 50 to 70 Years
  • 8.5.4 Older than 70 Years
• 8.6 By Gender
  • 8.6.1 Male
  • 8.6.2 Female
• 8.7 By End User
  • 8.7.1 Hospitals
  • 8.7.2 Specialty Clinics
  • 8.7.3 Rehabilitation Centers
  • 8.7.4 Others

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Patient Population Overview
  • 9.1.2 Epidemiology Trends
  • 9.1.3 Demand Drivers
  • 9.1.4 Regional Regulatory Overview
  • 9.1.5 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Patient Population Overview
  • 9.2.2 Epidemiology Trends
  • 9.2.3 Demand Drivers
  • 9.2.4 Regional Regulatory Overview
  • 9.2.5 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Patient Population Overview
  • 9.3.2 Epidemiology Trends
  • 9.3.3 Demand Drivers
  • 9.3.4 Regional Regulatory Overview
  • 9.3.5 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Patient Population Overview
  • 9.4.2 Epidemiology Trends
  • 9.4.3 Demand Drivers
  • 9.4.4 Regional Regulatory Overview
  • 9.4.5 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Patient Population Overview
  • 9.5.2 Epidemiology Trends
  • 9.5.3 Demand Drivers
  • 9.5.4 Regional Regulatory Overview
  • 9.5.5 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Global Regulatory Overview
• 11.2 United States Regulatory Framework (FDA)
• 11.3 Europe Regulatory Framework (EMA)
• 11.4 Japan Regulatory Framework (PMDA)
• 11.5 India Regulatory Framework (CDSCO)
• 11.6 China Regulatory Framework (NMPA)
• 11.7 Stroke Treatment Guidelines Assessment
• 11.8 Reimbursement Policies
• 11.9 Health Technology Assessment Landscape
• 11.10 Public Health Policies and Prevention Programs

12. Competitive Landscape

• 12.1 Market Structure Assessment
• 12.2 Market Share Analysis
• 12.3 Strategic Positioning Analysis
• 12.4 Product Portfolio Benchmarking
• 12.5 Pipeline Competitiveness Assessment
• 12.6 Strategic Collaborations
• 12.7 Licensing and Partnership Activities
• 12.8 Mergers and Acquisitions
• 12.9 SWOT Analysis
• 12.10 Competitive Dashboard

13. Company Profiles

• 13.1 Genentech
  • 13.1.1 Company Overview
  • 13.1.2 Approved Products Relevant to Stroke Management
  • 13.1.3 Key Indications
  • 13.1.4 Stroke-Related Research and Development Activities
  • 13.1.5 Pipeline Assets (Verified)
• 13.2 Boehringer Ingelheim
  • 13.2.1 Company Overview
  • 13.2.2 Approved Products
  • 13.2.3 Key Indications
  • 13.2.4 Stroke Prevention Portfolio
  • 13.2.5 Pipeline Assets (Verified)
• 13.3 F. Hoffmann-La Roche Ltd
  • 13.3.1 Company Overview
  • 13.3.2 Approved Products Relevant to Stroke Care
  • 13.3.3 Key Indications
  • 13.3.4 Neurology Portfolio Overview
  • 13.3.5 Pipeline Assets (Verified)
• 13.4 Novartis AG
  • 13.4.1 Company Overview
  • 13.4.2 Approved Products
  • 13.4.3 Key Indications
  • 13.4.4 Cardiovascular Risk Reduction Strategy
  • 13.4.5 Pipeline Assets (Verified)
• 13.5 Bayer AG
  • 13.5.1 Company Overview
  • 13.5.2 Approved Products
  • 13.5.3 Key Indications
  • 13.5.4 Stroke Prevention Portfolio
  • 13.5.5 Pipeline Assets (Verified)
• 13.6 Johnson & Johnson
  • 13.6.1 Company Overview
  • 13.6.2 Approved Products
  • 13.6.3 Medical Device Portfolio Relevant to Stroke
  • 13.6.4 Key Indications
  • 13.6.5 Pipeline Assets (Verified)
• 13.7 Daiichi Sankyo
  • 13.7.1 Company Overview
  • 13.7.2 Approved Products
  • 13.7.3 Key Indications
  • 13.7.4 Stroke Prevention Portfolio
  • 13.7.5 Pipeline Assets (Verified)
• 13.8 Sanofi
  • 13.8.1 Company Overview
  • 13.8.2 Approved Products Relevant to Stroke Risk Reduction
  • 13.8.3 Key Indications
  • 13.8.4 Cardiovascular Portfolio
  • 13.8.5 Pipeline Assets (Verified)
• 13.9 Novo Nordisk
  • 13.9.1 Company Overview
  • 13.9.2 Approved Products
  • 13.9.3 Key Indications
  • 13.9.4 Cardiometabolic Risk Reduction Strategy
  • 13.9.5 Pipeline Assets (Verified)
• 13.10 AstraZeneca PLC
  • 13.10.1 Company Overview
  • 13.10.2 Approved Products
  • 13.10.3 Key Indications
  • 13.10.4 Cardiovascular Portfolio
  • 13.10.5 Pipeline Assets (Verified)
• 13.11 Merck & Co., Inc.
  • 13.11.1 Company Overview
  • 13.11.2 Approved Products Relevant to Cardiovascular Risk Reduction
  • 13.11.3 Key Indications
  • 13.11.4 Strategic Initiatives
  • 13.11.5 Pipeline Assets (Verified)
• 13.12 GlaxoSmithKline plc
  • 13.12.1 Company Overview
  • 13.12.2 Approved Products Relevant to Stroke Prevention
  • 13.12.3 Key Indications
  • 13.12.4 Research Programs
  • 13.12.5 Pipeline Assets (Verified)
• 13.13 Eli Lilly and Company
  • 13.13.1 Company Overview
  • 13.13.2 Approved Products
  • 13.13.3 Key Indications
  • 13.13.4 Cardiometabolic Portfolio
  • 13.13.5 Pipeline Assets (Verified)
• 13.14 AbbVie Inc.
  • 13.14.1 Company Overview
  • 13.14.2 Approved Products Relevant to Stroke Care and Risk Reduction
  • 13.14.3 Key Indications
  • 13.14.4 Neuroscience Portfolio Overview
  • 13.14.5 Pipeline Assets (Verified)

14. Future Outlook

• 14.1 Future Epidemiology Trends
• 14.2 Emerging Risk Factor Trends
• 14.3 Advances in Stroke Prevention
• 14.4 Advances in Acute Stroke Treatment
• 14.5 Impact of Digital Health Technologies
• 14.6 Precision Medicine Outlook
• 14.7 Scenario Analysis
  • 14.7.1 Base Case
  • 14.7.2 Optimistic Case
  • 14.7.3 Conservative Case
• 14.8 Strategic Recommendations

15. Methodology

• 15.1 Research Objectives
• 15.2 Study Design
• 15.3 Data Collection Methodology
• 15.4 Epidemiology Modeling Framework
• 15.5 Forecasting Methodology
• 15.6 Data Validation and Triangulation
• 15.7 Assumptions and Limitations
• 15.8 Abbreviations
• 15.9 References and Sources
• 15.10 Analyst Credentials and Quality Control Framework